Bachem Holding AG
SIX:BANB

Watchlist Manager
Bachem Holding AG Logo
Bachem Holding AG
SIX:BANB
Watchlist
Price: 67.5 CHF -3.3% Market Closed
Market Cap: 5.1B CHF
Have any thoughts about
Bachem Holding AG?
Write Note

Bachem Holding AG
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Bachem Holding AG
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Bachem Holding AG
SIX:BANB
Cash & Cash Equivalents
CHf62.7m
CAGR 3-Years
46%
CAGR 5-Years
39%
CAGR 10-Years
10%
Siegfried Holding AG
SIX:SFZN
Cash & Cash Equivalents
CHf64.5m
CAGR 3-Years
3%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Lonza Group AG
SIX:LONN
Cash & Cash Equivalents
CHf1.2B
CAGR 3-Years
34%
CAGR 5-Years
24%
CAGR 10-Years
16%
Tecan Group AG
SIX:TECN
Cash & Cash Equivalents
CHf108.3m
CAGR 3-Years
-20%
CAGR 5-Years
-17%
CAGR 10-Years
N/A
PolyPeptide Group AG
SIX:PPGN
Cash & Cash Equivalents
€95.7m
CAGR 3-Years
77%
CAGR 5-Years
57%
CAGR 10-Years
N/A
SKAN Group AG
SIX:SKAN
Cash & Cash Equivalents
CHf85.1m
CAGR 3-Years
10%
CAGR 5-Years
191%
CAGR 10-Years
N/A
No Stocks Found

Bachem Holding AG
Glance View

Market Cap
5.1B CHF
Industry
Life Sciences Tools & Services

Bachem Holding AG engages in the provision of peptides and oligonucleotides. The company is headquartered in Bubendorf, Basel-Landschaft and currently employs 1,639 full-time employees. The company went IPO on 2001-06-29. The firm focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The firm markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.

BANB Intrinsic Value
90.95 CHF
Undervaluation 26%
Intrinsic Value
Price

See Also

What is Bachem Holding AG's Cash & Cash Equivalents?
Cash & Cash Equivalents
62.7m CHF

Based on the financial report for Jun 30, 2024, Bachem Holding AG's Cash & Cash Equivalents amounts to 62.7m CHF.

What is Bachem Holding AG's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
10%

Over the last year, the Cash & Cash Equivalents growth was -42%. The average annual Cash & Cash Equivalents growth rates for Bachem Holding AG have been 46% over the past three years , 39% over the past five years , and 10% over the past ten years .

Back to Top